ACH in three months: buy, wait or sell?
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
- Buy / Wait / Sell rating
- 3-month target price
- Bear · Base · Bull
- vs. the market
What happened with ACH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Accendra Health helps patients manage ongoing medical needs outside the hospital. Diabetes and sleep therapy together bring in most of its revenue; home respiratory care is another major line. It delivers supplies to patients and home health agencies, rents or sells equipment such as oxygen and sleep-apnea devices, and provides patient support. Having sold its Products & Healthcare Services business, it now focuses on home healthcare while retaining a minority stake in the sold business.
Commercial insurers, Medicare and Medicaid pay for the equipment, supplies and services, alongside payments from patients and home health agencies. Accendra Health charges for individual items and services and also has arrangements that pay a fixed amount per covered patient, known as capitation. Two large commercial payors supply a substantial share of revenue. The largest has moved to end certain contracts that accounted for nearly all of the company's capitation revenue.
The business depends on payment rates and on hospitals and physicians referring patients who need care at home. Most of those referral relationships are not secured by contracts or exclusive arrangements, and federal and state laws restrict them. To bill Medicare and Medicaid, the company must provide medically necessary services with supporting documentation and accurate billing codes.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Accendra Health faces home-equipment rivals Lincare, Rotech and Quipt Home Medical, but reimbursement and the loss of contracts representing 12% of its 2025 revenue matter most to its near-term results.
AdaptHealth competes with Accendra Health for home patients needing sleep-apnea equipment, respiratory therapy and diabetes devices and supplies; Accendra receives payment from insurers, government programs, home health agencies and patients. Watch AdaptHealth’s sleep and diabetes businesses for competition in Accendra’s two largest revenue categories.
Viemed Healthcare competes with Accendra Health in home ventilation, oxygen therapy and sleep-apnea equipment and services, earning respiratory revenue mainly from monthly equipment rentals, related supplies and in-home clinical services. Its home-ventilation business is the clearest area to watch for competition affecting Accendra’s home respiratory revenue.
Cardinal Health’s at-Home Solutions competes with Accendra Health by supplying medical products to home patients with chronic conditions, both directly and through home-care businesses. Watch that business rather than Cardinal’s overall results, which are dominated by pharmaceuticals and other medical-product businesses serving customers such as hospitals and pharmacies.
Fed Interest Rate Decision
Accendra Health’s Fed-linked floating-rate loans and revolving borrowings can cost more or less as interest rates change, affecting cash left for its home-health operations and debt repayment.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can raise interest costs on debt that reprices, leaving less cash for Accendra Health to run its home-health business and repay debt.
If it comes in below expectations
Lower rates can ease interest costs on debt that reprices, leaving Accendra Health more cash for its home-health business and debt repayment.
Accendra Health, Inc. earningsThis company
Accendra Health's report will show whether its remaining home-care business can steady revenue and cash flow as it transitions away from major payor contracts.
Read continuing-operations revenue alongside operating cash flow. Steady revenue with contained cash use would show that diabetes, sleep and respiratory services are absorbing the contract wind-down; falling revenue or heavier cash use would show that lost contracts and separation costs are outweighing the retained business.
AdaptHealth Corp. earningsAHCO
AdaptHealth's sleep and diabetes businesses will show whether demand is holding in two markets where it competes with Accendra Health for home patients.
Look for whether AdaptHealth's sleep and diabetes businesses sustain revenue and patient demand. Strength in both would point to firm home-patient demand supporting Accendra Health's two largest categories; weakness would signal that softer demand or competition could weigh on Accendra's related sales.